# LuPARP (NCT03874884)

> 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: 177Lu-PSMA-617 plus olaparib
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03874884
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions: Olaparib; 177Lu-PSMA
- Enrollment: 70
- Primary outcome: Dose Limiting toxicities (DLTs)
- Primary outcome: Maximum Tolerated dose (MTD)
- Primary outcome: Recommended Phase 2 Dose (RP2D)

## Questions raised in the commentary

_Automated from all 37 indexed sources (Jun 2022 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether olaparib adds benefit over lutetium PSMA alone
- Whether LuPARP warrants larger randomized confirmation
- Whether DNA-repair status should guide selection for the combination

Also discussed: DNA-damage synergy, CTC response tracking, other Lu-PSMA combinations.

## Indexed commentary on LuPARP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 23
- YouTube: 8
- Podcasts: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=luparp-nct03874884

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03874884", "email": "<work email>"}; the inbox owner confirms by the emailed link.